Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3759 vs EGFR-TKIs in EGFR-mutant NSCLC with CNS metastases (first-line)
CTR20180609Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zorifertinib in non-small cell lung cancer (NSCLC), EGFR-mutated non-small cell lung cancer, brain metastases, sponsored by AstraZeneca. Started Aug 2018; status: completed.
02
Drugs
zorifertinib
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancerbrain metastases
Beyond the preview
Go deeper on CTR20180609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180609.